KR20110058818A - 암 치료를 위한 유기 비소 화합물 및 방법 - Google Patents

암 치료를 위한 유기 비소 화합물 및 방법 Download PDF

Info

Publication number
KR20110058818A
KR20110058818A KR1020117006250A KR20117006250A KR20110058818A KR 20110058818 A KR20110058818 A KR 20110058818A KR 1020117006250 A KR1020117006250 A KR 1020117006250A KR 20117006250 A KR20117006250 A KR 20117006250A KR 20110058818 A KR20110058818 A KR 20110058818A
Authority
KR
South Korea
Prior art keywords
alkyl
lymphoma
compound
aralkyl
hodgkin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020117006250A
Other languages
English (en)
Korean (ko)
Inventor
브라이언 에릭 슈와르츠
조나단 르위스
필립 비. 코마르니츠키
Original Assignee
지오팜 온콜로지 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 지오팜 온콜로지 인코포레이티드 filed Critical 지오팜 온콜로지 인코포레이티드
Publication of KR20110058818A publication Critical patent/KR20110058818A/ko
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • A61K31/285Arsenic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020117006250A 2008-08-20 2009-08-14 암 치료를 위한 유기 비소 화합물 및 방법 Ceased KR20110058818A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18951108P 2008-08-20 2008-08-20
US61/189,511 2008-08-20

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020177024240A Division KR20170103023A (ko) 2008-08-20 2009-08-14 암 치료를 위한 유기 비소 화합물 및 방법

Publications (1)

Publication Number Publication Date
KR20110058818A true KR20110058818A (ko) 2011-06-01

Family

ID=41707414

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020117006250A Ceased KR20110058818A (ko) 2008-08-20 2009-08-14 암 치료를 위한 유기 비소 화합물 및 방법
KR1020177024240A Ceased KR20170103023A (ko) 2008-08-20 2009-08-14 암 치료를 위한 유기 비소 화합물 및 방법
KR1020187026317A Ceased KR20180103194A (ko) 2008-08-20 2009-08-14 암 치료를 위한 유기 비소 화합물 및 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020177024240A Ceased KR20170103023A (ko) 2008-08-20 2009-08-14 암 치료를 위한 유기 비소 화합물 및 방법
KR1020187026317A Ceased KR20180103194A (ko) 2008-08-20 2009-08-14 암 치료를 위한 유기 비소 화합물 및 방법

Country Status (19)

Country Link
US (4) US20110269697A1 (enExample)
EP (2) EP3388111B1 (enExample)
JP (5) JP5933896B2 (enExample)
KR (3) KR20110058818A (enExample)
CN (2) CN102149432A (enExample)
AU (1) AU2009282972A1 (enExample)
BR (1) BRPI0918407A2 (enExample)
CA (1) CA2734650A1 (enExample)
DK (2) DK3388111T3 (enExample)
ES (2) ES2901426T3 (enExample)
HK (1) HK1212218A1 (enExample)
IL (1) IL211153A0 (enExample)
MX (1) MX2011001800A (enExample)
NZ (1) NZ591181A (enExample)
PT (2) PT2321012T (enExample)
RU (1) RU2534606C2 (enExample)
SG (3) SG10201810450QA (enExample)
WO (1) WO2010021928A1 (enExample)
ZA (1) ZA201101216B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI617305B (zh) * 2013-12-05 2018-03-11 蘇愛康制藥有限公司 治療癌症的化合物及其應用程序
CN104151397A (zh) * 2014-07-03 2014-11-19 北京大学 一类新型三硫杂二环有机砷化物及其合成方法和在抗肿瘤领域里的应用
JP6413969B2 (ja) * 2015-07-29 2018-10-31 住友金属鉱山株式会社 日射遮蔽体形成用分散液および当該分散液を用いた日射遮蔽体
WO2019220961A1 (ja) * 2018-05-18 2019-11-21 ソレイジア・ファーマ株式会社 ダリナパルシンのアルカリ金属塩及び/又は無機酸付加塩の結晶型及びその製剤
US11998654B2 (en) 2018-07-12 2024-06-04 Bard Shannon Limited Securing implants and medical devices
CN113408945B (zh) * 2021-07-15 2023-03-24 广西中烟工业有限责任公司 一种烤烟纯度的检测方法、装置、电子设备及存储介质

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US234972A (en) 1880-11-30 William ennis
US761900A (en) 1904-03-05 1904-06-07 Newton Jefferson Norman Flux compound.
US2349729A (en) 1940-08-24 1944-05-23 Parke Davis & Co Therapeutic arsenic preparation
WO1999018798A1 (en) 1997-10-15 1999-04-22 Polarx Biopharmaceuticals, Inc. Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
IL136051A0 (en) 1997-11-10 2001-05-20 Sloan Kettering Inst Cancer Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
CN1233476A (zh) 1998-04-24 1999-11-03 陆道培 治疗急性白血病的药物及其制备方法
EP1002537A1 (en) 1998-10-30 2000-05-24 Assistance Publique, Hopitaux De Paris Use of melarsoprol for the manufacture of a medicament for treating B-cell lymphoproliferative diseases, such as multiple myeloma
US6191123B1 (en) 1999-03-19 2001-02-20 Parker Hughes Institute Organic-arsenic compounds
CN1443064A (zh) 2000-04-26 2003-09-17 俄勒冈健康科学大学 施用含硫醇化学保护化合物的方法
DE10132625A1 (de) 2001-07-05 2003-01-23 Oce Printing Systems Gmbh Verfahren, Computerprogrammprodukt und Gerätesystem zum visuellen Überprüfen von Bilddaten
EP2462932A1 (en) 2002-01-07 2012-06-13 Board Of Regents, The University Of Texas System S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer
TW201440760A (zh) * 2004-07-16 2014-11-01 Texas A & M Univ Sys 有機砷化合物、其用於治療癌症之用途及包含其之醫藥組成物
ES2532666T3 (es) 2005-07-29 2015-03-30 Solasia Pharma K.K. Compuestos y métodos para el tratamiento del cáncer
CN104109177A (zh) * 2006-01-13 2014-10-22 得克萨斯州A&M大学系统 用于治疗癌症的化合物和方法
TW200829261A (en) 2006-09-29 2008-07-16 Ziopharm Oncology Inc Method for controlling angiogenesis in animals
CA2694983A1 (en) * 2007-07-17 2009-01-22 Combinatorx, Incorporated Treatments of b-cell proliferative disorders
CA2694987A1 (en) * 2007-07-17 2009-01-22 Combinatorx, Incorporated Combinations for the treatment of b-cell proliferative disorders
KR20100100835A (ko) * 2007-11-02 2010-09-15 지오팜 온콜로지 인코포레이티드 유기 비소제와의 병용 요법
WO2009151569A2 (en) * 2008-06-09 2009-12-17 Combinatorx, Incorporated Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders

Also Published As

Publication number Publication date
US11324714B2 (en) 2022-05-10
DK2321012T3 (en) 2018-12-03
SG10201810449XA (en) 2018-12-28
EP3388111B1 (en) 2021-09-29
US20210038556A1 (en) 2021-02-11
SG10201403869TA (en) 2014-10-30
CN102149432A (zh) 2011-08-10
JP2017002081A (ja) 2017-01-05
JP5933896B2 (ja) 2016-06-15
WO2010021928A1 (en) 2010-02-25
DK3388111T3 (da) 2021-12-06
US10842769B2 (en) 2020-11-24
ZA201101216B (en) 2011-10-26
JP6315841B2 (ja) 2018-04-25
HK1212218A1 (en) 2016-06-10
IL211153A0 (en) 2011-04-28
MX2011001800A (es) 2011-04-04
CN104800828A (zh) 2015-07-29
EP2321012A4 (en) 2011-10-05
US20210038557A1 (en) 2021-02-11
EP3388111A1 (en) 2018-10-17
SG10201810450QA (en) 2018-12-28
KR20170103023A (ko) 2017-09-12
CA2734650A1 (en) 2010-02-25
KR20180103194A (ko) 2018-09-18
US20110269697A1 (en) 2011-11-03
JP2012500271A (ja) 2012-01-05
RU2534606C2 (ru) 2014-11-27
PT2321012T (pt) 2019-01-11
JP2014148552A (ja) 2014-08-21
JP2015120755A (ja) 2015-07-02
ES2703740T3 (es) 2019-03-12
EP2321012A1 (en) 2011-05-18
HK1254607A1 (en) 2019-07-26
BRPI0918407A2 (pt) 2015-11-24
JP2018039853A (ja) 2018-03-15
PT3388111T (pt) 2021-12-23
EP2321012B1 (en) 2018-10-10
US11324713B2 (en) 2022-05-10
AU2009282972A1 (en) 2010-02-25
US20150231107A1 (en) 2015-08-20
RU2011110392A (ru) 2012-09-27
JP5976036B2 (ja) 2016-08-23
NZ591181A (en) 2012-09-28
ES2901426T3 (es) 2022-03-22

Similar Documents

Publication Publication Date Title
JP5745660B2 (ja) 癌の治療のための化合物および方法
US11324714B2 (en) Organoarsenic compounds and methods for the treatment of cancer
KR101471498B1 (ko) 암의 치료를 위한 화합물 및 방법
HK1157694B (en) Organoarsenic compounds and methods for the treatment of cancer
HK1157694A (en) Organoarsenic compounds and methods for the treatment of cancer
HK1254607B (en) Organoarsenic compound for the treatment of cancer
JP2016540775A (ja) 癌の処置のための化合物および方法
HK1130804B (en) Compounds and methods for the treatment of cancer
AU2013270520A1 (en) Compounds and methods for treatment of cancer

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20110318

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20140730

Comment text: Request for Examination of Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20150624

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20151020

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20160627

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20151020

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20160627

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20160420

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20140730

Comment text: Amendment to Specification, etc.

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20161020

Patent event code: PE09021S01D

AMND Amendment
PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20170530

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20170420

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20161020

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20160926

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20160627

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20160420

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20151020

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20140730

PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20170829